CMS has obtained the clinical trial approval notice for the new indication of chronic obstructive pulmonary disease for the Class 1 new drug MG-K10 humanized monoclonal antibody injection
I'm PortAI, I can summarize articles.
CMS has received approval from the National Medical Products Administration (NMPA) of China to conduct clinical trials for the Class 1 new drug MG-K10 humanized monoclonal antibody injection in chronic obstructive pulmonary disease (COPD). The co-development rights and exclusive commercialization rights for the drug are owned by CMS, and the approval notice was issued on September 29, 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments